Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre

Background: Hospitalised exacerbations of non-cystic fibrosis bronchiectasis are clinically heterogeneous, yet inpatient microbiology and management remain incompletely characterised. Methods: We retrospectively analysed 53 consecutive hospitalisations in 47 adults (2023–2024), describing respiratory severity, microbiological findings, antimicrobial exposure, corticosteroid use and length of stay (LOS), without a comparator group. Results: Acute respiratory failure was documented in 12/53 episodes (22.6%), and Pseudomonas aeruginosa was isolated in 19/53 (35.8%). An exploratory four-domain classification (bacteria, nontuberculous mycobacteria, fungi and viruses), incorporating historical and acute findings, identified ≥2 domains in 24/53 episodes (45.3%); median LOS was 18.5 versus 15 days for ≥2 versus 0–1 domains. Intravenous antibacterials were recorded in 51/53 episodes (96.2%) and inhaled amikacin in 28/53 (52.8%). Median systemic antibacterial treatment duration, calculated from recorded concurrent antibiotic courses, was 11 days during hospitalisation and 11.5 days including documented pretreatment. Systemic corticosteroids were recorded in 28/53 episodes (52.8%), including 15/30 without documented COPD or asthma. Overall median LOS was 16 days (IQR 12–20), with one in-hospital death (1.9%). Conclusions: Hospitalised exacerbations involved heterogeneous microbiological findings and frequent acute inhaled antibiotic and systemic corticosteroid use. The overlap–LOS contrast is descriptive, not prognostic, and reconstructed durations cannot establish treatment appropriateness. Prospective studies should assess prescribing indications, microbiological context and clinical response.

Authors

Institutions

Publication Details

Journal
Diseases
Published
2026-11-18
DOI
https://doi.org/10.3390/diseases14110427
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre

Alessandro Cascina, Valentina Conio, Angelo Guido Corsico, Giulia Maria Stella et al.
1 links
Diseases
Cystic Fibrosis Research Advances
article

Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre

Alessandro Cascina, Valentina Conio, Angelo Guido Corsico, Giulia Maria Stella, Francesco Rocco Bertuccio, Paolo Cosseta Reposi, Lorenzo Arlando, Lucrezia Pisanu, Mitela Tafa, Maria Arminio, Elisabetta Gallo
article en

Abstract

Background: Hospitalised exacerbations of non-cystic fibrosis bronchiectasis are clinically heterogeneous, yet inpatient microbiology and management remain incompletely characterised. Methods: We retrospectively analysed 53 consecutive hospitalisations in 47 adults (2023–2024), describing respiratory severity, microbiological findings, antimicrobial exposure, corticosteroid use and length of stay (LOS), without a comparator group. Results: Acute respiratory failure was documented in 12/53 episodes (22.6%), and Pseudomonas aeruginosa was isolated in 19/53 (35.8%). An exploratory four-domain classification (bacteria, nontuberculous mycobacteria, fungi and viruses), incorporating historical and acute findings, identified ≥2 domains in 24/53 episodes (45.3%); median LOS was 18.5 versus 15 days for ≥2 versus 0–1 domains. Intravenous antibacterials were recorded in 51/53 episodes (96.2%) and inhaled amikacin in 28/53 (52.8%). Median systemic antibacterial treatment duration, calculated from recorded concurrent antibiotic courses, was 11 days during hospitalisation and 11.5 days including documented pretreatment. Systemic corticosteroids were recorded in 28/53 episodes (52.8%), including 15/30 without documented COPD or asthma. Overall median LOS was 16 days (IQR 12–20), with one in-hospital death (1.9%). Conclusions: Hospitalised exacerbations involved heterogeneous microbiological findings and frequent acute inhaled antibiotic and systemic corticosteroid use. The overlap–LOS contrast is descriptive, not prognostic, and reconstructed durations cannot establish treatment appropriateness. Prospective studies should assess prescribing indications, microbiological context and clinical response.

DiseasesVol. 14(11)
University of Pavia (IT), Policlinico San Matteo Fondazione (IT)
Good health and well-being
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon